If researchers conclude that a new cancer drug is effective but the results are not replicable, what is the most likely reason for this?

• A. Experimental error in drug formulation
• B. Observer bias in recording data
• C. Differences in patient population
• D. Insufficient sample size during original study

Answer: (B)

The conclusion that a new cancer drug is effective is based on the results of the original study; however, if these results are not replicable, it suggests that there could be some influence interfering with the validity of the findings. Observer bias, which occurs when those conducting the study have preconceived notions or expectations that influence their data recording and analysis, raises concerns about the reliability of the results.

In particular, if observers or researchers are aware of participants' treatment status (whether they received the drug or a placebo), it might affect their interpretation of outcomes. This bias can lead to inflated or skewed results that do not hold true when subjected to subsequent studies, which would explain why replicating the study yields different results.

The other options, while they may play a role in research integrity, do not directly address the issue of why the initial results might not be replicated as strongly as observer bias does. For example, experimental error in drug formulation might lead to ineffective treatment rather than an overestimation of efficacy, and differences in patient population usually highlight variability in results rather than replication failure due to subjective reporting. Insufficient sample size could lead to statistical errors, but it does not necessarily imply that the original conclusions were biased; hence, observer bias is the